Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
Want to see TRIB full AI Analyst Report?
Top Page
Trinity Biotech
(NASDAQ:TRIB)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.57
▼(-23.73% Downside)
Action:Downgraded
Date:05/07/26
TRIB scores low primarily due to weak financial performance (sustained losses, negative equity, higher leverage, and continued cash burn). Technical indicators also point to a weak downtrend with negative momentum. Valuation is difficult to justify using P/E because the company is loss-making, and no dividend support is provided.
Positive Factors
IFCC Gold HbA1c Certification
Earning the sole IFCC Gold classification provides durable clinical credibility and differentiation in lab HbA1c testing. That accreditation supports payer confidence, easier laboratory adoption and upsell of recurring reagents, strengthening long-term installed-base driven revenue in a large diabetes diagnostics market.
Negative Factors
Stressed balance sheet
Persistent negative equity and rising debt create ongoing solvency and refinancing risk, constraining strategic optionality. Over 2–6 months this fragility limits ability to invest in commercialization or R&D without dilutive financing or covenant relief and raises the chance of costly recapitalization.
Read all positive and negative factors
Positive Factors
Negative Factors
IFCC Gold HbA1c Certification
Earning the sole IFCC Gold classification provides durable clinical credibility and differentiation in lab HbA1c testing. That accreditation supports payer confidence, easier laboratory adoption and upsell of recurring reagents, strengthening long-term installed-base driven revenue in a large diabetes diagnostics market.
Read all positive factors
Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.09M
Dividend YieldN/A
Average Volume (3M)136.14K
Price to Earnings (P/E)―
Beta (1Y)2.28
Revenue Growth-28.57%
EPS Growth28.35%
CountryUS
Employees380
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.01
Shares Outstanding18,720,331
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.20
Price to Sales (P/S)0.33
P/FCF Ratio-2.32
Enterprise Value/Market Cap11.51
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda-16.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$59.50M
Trinity Biotech Business Overview & Revenue Model
Company Description
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clini...
How the Company Makes Money
Trinity Biotech primarily makes money by selling in vitro diagnostic products—typically a combination of (1) instruments/analyzers (where applicable) and (2) recurring consumables such as reagents, test kits, and related supplies used per test. In...
Trinity Biotech Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.Positive Updates
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Negative Updates
Hemoglobin Revenue Decline
Hemoglobin revenues from A1c testing products were lower in Q3 2024 compared to Q3 2023, due to uneven ordering patterns and decreased instrument sales.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Read all positive updates
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.Trinity Biotech Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.92M | 61.55M | 56.83M | 62.52M | 81.15M |
| Gross Profit | 15.55M | 21.44M | 19.45M | 22.05M | 33.45M |
| EBITDA | -8.26M | -16.91M | -24.10M | -16.71M | 10.59M |
| Net Income | -37.49M | -31.79M | -24.02M | -41.00M | 875.00K |
Balance Sheet | |||||
| Total Assets | 105.17M | 103.29M | 59.44M | 92.10M | 118.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5.14M | 5.17M | 3.69M | 6.58M | 25.91M |
| Total Debt | 137.98M | 100.76M | 67.43M | 72.20M | 99.16M |
| Total Liabilities | 177.15M | 138.47M | 83.38M | 94.28M | 119.21M |
| Stockholders Equity | -71.98M | -35.18M | -23.95M | -2.18M | -319.00K |
Cash Flow | |||||
| Free Cash Flow | -6.34M | -14.26M | -12.36M | -6.90M | 4.55M |
| Operating Cash Flow | -6.26M | -4.19M | -11.56M | -921.00K | 13.24M |
| Investing Cash Flow | -6.24M | -22.97M | 24.76M | -5.98M | -8.69M |
| Financing Cash Flow | 12.40M | 28.81M | -16.04M | -12.32M | -6.02M |
Trinity Biotech Technical Analysis
Neutral
0.75
Price Trends
0.64
Negative
0.70
Negative
0.90
Negative
Market Momentum
-0.02
Negative
46.70
Neutral
56.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Neutral. The current price of 0.75 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.64, and below the 200-day MA of 0.90, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.70 is Neutral, neither overbought nor oversold. The STOCH value of 56.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRIB.
Trinity Biotech Risk Analysis
Trinity Biotech disclosed 1 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Trinity Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $43.90M | -7.72 | -6.73% | ― | 28.97% | 75.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $14.23M | ― | -71.38% | ― | 0.96% | 91.13% | |
45 Neutral | $6.29M | -0.47 | -174.16% | ― | 33.26% | 49.65% | |
43 Neutral | $7.35M | -1.19 | -245.18% | ― | -35.75% | 47.29% | |
40 Underperform | $12.09M | -0.39 | 80.66% | ― | -28.57% | 28.35% |
* Healthcare Sector Average
TRIB
Trinity Biotech
0.60
-0.09
-13.13%
PRPO
Precipio
23.80
14.12
145.87%
BNGO
BioNano Genomics
1.24
-2.48
-66.67%
INBS
Intelligent Bio Solutions
2.57
-11.53
-81.77%
BIAF
bioAffinity Technologies, Inc.
1.56
-6.30
-80.15%
Trinity Biotech Corporate Events
Trinity Biotech Names North America Commercial Head as Transformation Plan Starts to Lift Margins
May 6, 2026
On May 1, 2026, Trinity Biotech appointed industry veteran Jerry Lydon as Head of North America Commercial Operations, a move aimed at strengthening sales execution, channel management, and profitability as the company shifts from restructuring to...
Trinity Biotech Reports Strong EpiCapture Prostate Cancer Trial Results and Secures Debt Covenant Waiver
Mar 25, 2026
On March 23, 2026, Trinity Biotech announced successful clinical results for an enhanced version of its EpiCapture prostate cancer test, which now uses a machine learning algorithm that integrates DNA biomarkers with patient features such as ethni...
Trinity Biotech Targets Diabetes Growth With CGM Push and Brazil HbA1c Rollout
Mar 16, 2026
On March 11, 2026, Trinity Biotech said senior executives would attend the ATTD 2026 diabetes conference in Barcelona to pursue strategic collaborations and commercialization plans for its next‑generation Continuous Glucose Monitoring platfo...
Trinity Biotech Reports Major Technical Breakthroughs in Next-Generation CGM+ Platform
Mar 10, 2026
On March 10, 2026, Trinity Biotech announced significant technical advancements in its next-generation CGM+ continuous glucose monitoring platform, following more than 650 days of clinical testing on an updated sensor and electronics architecture....
Trinity Biotech Flags Lower Q4 2025 Revenue as It Accelerates Manufacturing Shift and Growth Plan
Mar 10, 2026
On March 10, 2026, Trinity Biotech issued a trading and business update indicating it expects fourth-quarter 2025 revenue of approximately $11.5 million to $12.5 million, down from $15.9 million a year earlier, mainly due to global HIV testing mar...
Trinity Biotech Sets Up $25 Million Standby Equity Facility to Fund Growth
Feb 25, 2026
On February 24, 2026, Trinity Biotech plc entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. that gives the company the right, at its discretion, to sell up to $25 million of American Depositary Shares over time, subject to an ef...
Trinity Biotech Warned by Nasdaq Over Minimum Public Float Value
Feb 20, 2026
On February 19, 2026, Trinity Biotech received a notice from Nasdaq that it no longer meets the Nasdaq Global Select Market requirement to maintain a minimum $15 million market value of publicly held shares over 30 consecutive business days. The c...
Trinity Biotech Faces Nasdaq Bid-Price Deficiency, Given Until August to Regain Compliance
Feb 13, 2026
On February 11, 2026, Trinity Biotech received a notice from Nasdaq that its American Depositary Shares had failed for 30 consecutive business days to meet the exchange’s minimum bid price requirement of $1.00 per share. The ADSs will contin...
Trinity Biotech’s Premier Hb9210 Wins Sole IFCC Gold HbA1c Classification for 2026
Feb 13, 2026
On February 10, 2026, Trinity Biotech announced that its Premier Hb9210 HbA1c Analyser, equipped with the next‑generation Buffer A Plus column system for laboratory testing, received the International Federation of Clinical Chemistry and Lab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.